Comparison of the metabolic parameters and androgen level of umbilical cord blood in newborns of mothers with polycystic ovary syndrome and controls

Journal of Research in Medical Sciences

Volumn 17, Issue 3, 2012, Pages 28-32

  Mehrabian, Ferdous ^a   Kelishadi, Roya ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Androgen; Metabolism; Neonate; Polycystic ovary syndrome; Pregnancy

Indexed keywords

ANDROGEN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIRTH WEIGHT; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMMUNOASSAY; INFANT; METABOLIC PARAMETERS; NEWBORN; OVARY POLYCYSTIC DISEASE; PHYSICAL EXAMINATION; UMBILICAL CORD BLOOD; WEIGHT GAIN;

EID: 84859132248     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Paneth N, Susser M. Early origin of coronary heart disease (the "Barker hypothesis"). BMJ 1995;310:411-2.
2. Rinaudo P, Wang E. Fetal Programming and Metabolic Syndrome. Annu Rev Physiol 2012;74:107-30.
3. Hodyl NA, Stark MJ, Osei-Kumah A, Clifton VL. Prenatal programming of the innate immune response following in utero exposure to inflammation: a sexually dimorphic process? Expert Rev Clin Immunol 2011;7:579-92.
4. Briana DD, Malamitsi-Puchner A. Intrauterine growth restriction and adult disease: The role of adipocytokines. Eur J Endocrinol 2009;160:337-47.
5. Artini PG, Di Berardino OM, Simi G, Papini F, Ruggiero M, Monteleone P, et al. Best methods for identification and treatment of PCOS. Minerva Ginecol 2010;62:33-48.
6. Mehrabian F, Khani B, Kelishadi R, Ghanbari E. The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria. Endokrynol Pol 2011;62:238-42.
7. Kosmala W, O'Moore-Sullivan TM, Plaksej R, Kuliczkowska-Plaksej J, Przewlocka-Kosmala M, Marwick TH. Subclinical impairment of left ventricular function in young obese women: Contributions of polycystic ovary disease and insulin resistance. J Clin Endocrinol Metab 2008;93:3748-54.
8. Koiou E, Dinas K, Tziomalos K, Toulis K, Kandaraki EA, Kalaitzakis E, et al. The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria. Obes Facts 2011;4:145-50.
9. Cupisti S, Kajaia N, Dittrich R, Duezenli H, W Beckmann M, Mueller A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 2008;158:711-9.
10. Diamanti-Kandarakis E, Katsikis I, Piperi C, Kandaraki E, Piouka A, Papavassiliou AG, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008;69:634-41.
11. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005;106:131-7.
12. Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril 2010;93:1938-41.
13. Pall ME, Lao MC, Patel SS, Lee ML, Ghods DE, Chandler DW, et al. Testosterone and bioavailable testosterone help to distinguish between mild Cushing's syndrome and polycystic ovarian syndrome. Horm Metab Res 2008;40:813-8.
14. Puurunen J, Piltonen T, Jaakkola P, Ruokonen A, Morin-Papunen L, Tapanainen JS. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:1973-8.
15. Schulpis KH, Margeli A, Akalestos A, Vlachos GD, Partsinevelos GA, Papastamataki M, et al. Effects of mode of delivery on maternal-neonatal plasma antioxidant status and on protein S100B serum concentrations. Scand J Clin Lab Invest 2006;66:733-42.
16. Wells JC. Historical cohort studies and the early origins of disease hypothesis: Making sense of the evidence. Proc Nutr Soc 2009;68:179-88.
17. Woollett LA. Review: Transport of maternal cholesterol to the fetal circulation. Placenta 2011;32 Suppl 2:S218-21.
18. Kelishadi R, Badiee Z, Adeli K. Cord blood lipid profile and associated factors: baseline data of a birth cohort study. Paediatr Perinat Epidemiol 2007;21:518-24.
19. Badiee Z, Kelishadi R. Cord blood lipid profile in a population of Iranian term newborns. Pediatr Cardiol 2008;29:574-9.
20. Kharb S, Kaur R, Singh V, Sangwan K. Birth weight, cord blood lipoprotein and apolipoprotein levels in Indian newborns. Int J Prev Med 2010;1:29-33.
21. Desoye G, Gauster M, Wadsack C. Placental transport in pregnancy pathologies. Am J Clin Nutr 2011;94(6 Suppl):1896S-902S.
22. Rebholz SL, Burke KT, Yang Q, Tso P, Woollett LA. Dietary fat impacts fetal growth and metabolism: Uptake of chylomicron remnant core lipids by the placenta. Am J Physiol Endocrinol Metab 2011;301:E416-25.
23. Maliqueo M, Echiburú B, Crisosto N, Amigo P, Aranda P, Sánchez F, et al. Metabolic parameters in cord blood of newborns of women with polycystic ovary syndrome. Fertil Steril 2009;92:277-82.
24. Sathishkumar K, Elkins R, Yallampalli U, Balakrishnan M, Yallampalli C. Fetal programming of adult hypertension in female rat offspring exposed to androgens in utero. Early Hum Dev 2011;87:407-14.
25. Manikkam M, Crespi EJ, Doop DD, Herkimer C, Lee JS, Yu S, et al. Fetal programming: prenatal testosterone excess leads to fetal growth retardation and postnatal catch-up growth in sheep. Endocrinology 2004;145:790-8.
26. Steckler T, Wang J, Bartol FF, Roy SK, Padmanabhan V. Fetal programming: prenatal testosterone treatment causes intrauterine growth retardation, reduces ovarian reserve and increases ovarian follicular recruitment. Endocrinology 2005;146:3185-93.
27. Crespi EJ, Steckler TL, Mohankumar PS, Padmanabhan V. Prenatal exposure to excess testosterone modifies the developmental trajectory of the insulin-like growth factor system in female sheep. J Physiol 2006;572:119-30.
28. Eberle C. [Fetal programming of type 2 diabetes--intrauterine growth retardation (IUGR) as risk factor?]. MMW Fortschr Med 2010;152 Suppl 3:76-82.
29. Remacle C, Bieswal F, Bol V, Reusens B. Developmental programming of adult obesity and cardiovascular disease in rodents by maternal nutrition imbalance. Am J Clin Nutr 2011;94(6 Suppl):1846S-52S.
30. Sebert S, Sharkey D, Budge H, Symonds ME. The early programming of metabolic health: is epigenetic setting the missing link? Am J Clin Nutr 2011;94(6 Suppl):1953S-8S.
31. Achard V, Boullu-Ciocca S, Desbriére R, Grino M. Perinatal programming of central obesity and the metabolic syndrome: Role of glucocorticoids. Metab Syndr Relat Disord 2006;4:129-37.
32. Simmons RA. Role of metabolic programming in the pathogenesis of beta-cell failure in postnatal life. Rev Endocr Metab Disord 2007;8:95-104.
33. Kovo M, Weissman A, Gur D, Levran D, Rotmensch S, Glezerman M. Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. J Matern Fetal Neonatal Med 2006;19:415-9.
34. Nawaz FH, Khalid R, Naru T, Rizvi J. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res 2008;34:832-7.
35. Bolton S, Cleary B, Walsh J, Dempsey E, Turner MJ. Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. Eur J Pediatr 2009;168:203-6.
36. Khattab S, Mohsen IA, Aboul Foutouh I, Ashmawi HS, Mohsen MN, van Wely M, et al. Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gynecol Endocrinol 2011;27:789-93.
37. De Leo V, Musacchio MC, Piomboni P, Di Sabatino A, Morgante G. The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. Eur J Obstet Gynecol Reprod Biol 2011;157:63-6.